

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD40; toll-like receptor 3 (TLR3); TLR4	<p>Studies in mice suggest that combining multiple adjuvants and antigen-targeting compounds could help treat tumors with low immunogenicity. In mice with poorly immunogenic, ovalbumin-expressing melanomas, a combination of an anti-CD40 antibody, a TLR3 ligand and a TLR4 ligand linked to ovalbumin triggered an immune response that caused tumor rejection in 50% of mice. The three-pronged therapy also protected mice against tumors lacking ovalbumin. Next steps include running toxicology, pharmacokinetic and pharmacodynamic studies on the combination approach.</p> <p>Digna Biotech S.L. is developing ways to use the fibronectin extra domain A to deliver antigens to TLR4-expressing cells.</p> <p>SciBX 4(16); doi:10.1038/scibx.2011.451 Published online April 21, 2011</p>	Patent application filed; available for licensing from Digna Biotech	<p>Aranda, F. <i>et al. Cancer Res.</i>; published online March 14, 2011; doi:10.1158/0008-5472.CAN-10-3259 Contact: Pablo Sarobe, University of Navarra, Navarra, Spain e-mail: psarobe@unav.es</p>